Business
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEA
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LYbHRS3_v8ob5T6A1Lc.4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).","length":587,"tagName":"p"},{"type":"text","content":"The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the first cohort, which demonstrated a favorable safety profile and preliminary efficacy signals, including reduced cravings and withdrawal symptoms.","length":438,"tagName":"p"},{"type":"text","content":"“We are pleased to announce the successful completion of treatment in the second cohort, within a month after receiving DSMB approval to continue enrollment, marking continued steady progress in our multinational Phase I/IIa trial,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This achievement reflects the dedication of our clinical sites and the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs. We look forward to upcoming data readouts and advancing toward subsequent cohorts.”","length":583,"tagName":"p"},{"type":"text","content":"The Phase I/IIa trial is a multinational, multicenter stud...